Navigation Links
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
Date:2/10/2009

>

"AR9281 operates within the third branch of the arachidonic acid pathway and represents a potentially more specific and selective approach to intervene in metabolic and inflammatory diseases. The first two branches of this critical regulatory pathway have been targeted by several commercially successful marketed anti-inflammatory drugs including Aspirin(R) (acetylsalicylic acid), Motrin(R) (ibuprofen), Singulair(R) (Montelukast) and Celebrex(R) (celecoxib). We designed our Phase IIa trial to further validate the role of s-EH in the pathophysiology of disease and to lay the groundwork for further exploration of s-EH inhibition in treating a broad range of serious diseases including type 2 diabetes, hypertension and inflammatory disorders," commented Randall Whitcomb, M.D., Chief Medical Officer of Arete.

The results of a Phase I clinical program consisting of two double-blind, placebo-controlled studies demonstrated that AR9281 was safe and well tolerated in healthy volunteers. The studies met all safety, tolerability, pharmacokinetic and pharmacodynamic endpoints. In addition, AR9281 has shown favorable results in various published and proprietary in vitro and in vivo assays for potency, selectivity, efficacy, ADME, toxicity and safety.

About Arete Therapeutics Inc.

Arete Therapeutics is a privately-held biotechnology company dedicated to the discovery and development of novel drugs to treat type 2 diabetes, hypertension and inflammatory disorders. It is the world's leading company focused on s-EH, an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology. The Company was founded by Dr. Bruce Hammock, a Professor at the University of California, Davis, who discovered s-EH. The Company has raised a total of over $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Part
'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
2. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
3. Arete Therapeutics Appoints Donald Santel to Board of Directors
4. CareTech Solutions Service Desk Equals Help Desk Plus
5. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
8. Prime Therapeutics Receives TIPPS Certification
9. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
10. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
11. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... NC (PRWEB) March 03, 2015 ... Dentist in Wilmington, NC has achieved Accredited ... Dentistry. , He achieved this accomplishment after ... oral examinations, as well as the submission of ... Edgerton of Wilmington, NC grew up in Connecticut, ...
(Date:3/3/2015)... Viejo, California (PRWEB) March 03, 2015 ... animated effect entitled inMotion3D Environment from Pixel Film Studios. ... a 2D HDRI image into 360° viewing area inside ... Studios. “inMotion3D Environment blurs the line between professional and ... Motion 5 users can turn their 2D HDRI images ...
(Date:3/3/2015)... March 03, 2015 Aureus Medical Group ... Physician jobs, has announced that it will participate as ... held Tuesday, March 17, 2015 in St. Louis, MO. ... to meet job-seeking residents and fellows in a comfortable, ... division will be available to speak with attendees ...
(Date:3/3/2015)... California (PRWEB) March 03, 2015 ... announced the release of a new plugin FCPX3D Confetti ... Confetti animates an exploding transition using confetti particles inside ... “When adding an FCPX3D Confetti transition, users will have ... Plugin.” , Transition from one clip to the next ...
(Date:3/2/2015)... Atlanta, GA (PRWEB) March 02, 2015 ... FTX digital billboard design. The FTX uses state-of-the-art ... image quality, performance reliability, and owner satisfaction. An ... industry, is the exclusive Formetco 10 year LED Brightness ... was designed to be a superior billboard among any ...
Breaking Medicine News(10 mins):Health News:Dr. Edgerton, a Dentist in Wilmington, NC, Achieves Accredited Status in AACD 2Health News:A New Plugin Entitled inMotion3D Environment Was Released Today from Pixel Film Studios Exclusively for Motion 5 2Health News:A new Confetti Generator entitled FCPX3D Confetti was released today from Pixel Film Studios for Final Cut Pro X 2Health News:Formetco Launches Innovative LED Billboard System 2
... SPRING, Md., Jan. 30 Expanding the,pipeline of ... Microbicides (IPM) today announced that Pfizer Inc.,(Pfizer) has ... maraviroc, its,newly-approved HIV treatment, as a microbicide for ... trade name Selzentry(TM)/Celsentri(R),is one of a new class ...
... SALISBURY, Md., Jan. 30 Perdue AgriBusiness,has announced it ... Hi-Bred for the 2008 growing season to support the,marketplace ... the opportunity low lin soybeans bring to both,soybean growers ... who are,seeking to lower the trans fat content of ...
... found loss of consciousness increased chances of trauma the ... Researchers report that soldiers who have suffered concussions during ... post-traumatic stress disorder and other physical health problems. , ... health problems among those who had concussions versus those ...
... Class Team, JACKSON, Miss., Jan. 30 ... partner, announces the formation of the Outcome,Based ... home,industry,s only Enterprise Quality Improvement System., ... offers the industry new and unprecedented,benefits and ...
... Treatment Window as Area of,Greatest Dissatisfaction, According ... WALTHAM, Mass., Jan. 30 Decision ... advisory firms for pharmaceutical and,healthcare issues, finds ... despite recent negative results. Although,desmoteplase demonstrated efficacy ...
... LANCASTER, Pa., Jan. 30 Members of Highmark,s,FreedomBlue ... care options. Effective immediately, both routine and emergency,medical ... and Lancaster,Regional hospitals., "We,re pleased to partner ... and high-quality health care to people with Medicare ...
Cached Medicine News:Health News:IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide 2Health News:IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide 3Health News:Perdue AgriBusiness Announces Low Linolenic Soybean Contracting Opportunities with DuPont Business Pioneer Hi-Bred 2Health News:Perdue AgriBusiness Announces Low Linolenic Soybean Contracting Opportunities with DuPont Business Pioneer Hi-Bred 3Health News:Concussion Raises PTSD Risk for Iraq Vets 2Health News:Concussion Raises PTSD Risk for Iraq Vets 3Health News:Samarion(SM) Announces Formation of Outcome Based Study Team for Industry's Only Enterprise Quality Improvement System 2Health News:Samarion(SM) Announces Formation of Outcome Based Study Team for Industry's Only Enterprise Quality Improvement System 3Health News:Physicians Still Hopeful About Desmoteplase for the Treatment of Acute Ischemic Stroke Despite Negative Results 2Health News:Heart of Lancaster and Lancaster Regional Join Highmark Blue Shield Medicare Advantage Network 2
(Date:3/2/2015)... GERMANTOWN, Md., March 2, 2015  Intrexon Corporation ... synthetic biology, today announced its fourth quarter and ... Business Highlights and Recent Developments: , Acquired ... a new frontier in cellular therapeutics and other ... molecular engineering of food-grade microbes ( Lactococcus lactis ...
(Date:3/2/2015)... 2, 2015 BD (Becton, Dickinson and Company) ... technology company, today announced the acquisition of CRISI Medical ... technology company dedicated to improving the safety and delivery ... in helping address preventable medication errors and improve care ... an exclusive partnership in June 2013 to jointly develop ...
(Date:3/2/2015)... , March 2, 2015   Oriel STAT ... programs covering the most critical compliance and ... Medical device manufacturers are experiencing an industry-transforming ... more complex products, and global supply chains are ... US FDA and global regulators are increasing compliance ...
Breaking Medicine Technology:Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24BD Acquires CRISI Medical Systems 2BD Acquires CRISI Medical Systems 3Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 2Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 3
... First Commercial Vaccine,for Travellers' Diarrhoea Caused by ... ,Trial confirms good safety profile and strong ... -ACE BioSciences A/S, the,infectious diseases company is ... I clinical trials with its lead product,ACE393, ...
... able to stimulate insulin,release, TARRYTOWN, N.Y., March ... today results of two clinical,studies conducted in ... Gastroenterology and Hepatology,University Hospital Basel in Basel, ... peptide-1 (7-36 amide) (GLP-1) was to,establish the ...
Cached Medicine Technology:Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 2Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 3Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 4Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 2Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 3Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 4Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 5
... is designed to address customer requests for ... an even wider range of clinical applications ... color flow imaging with super-high frame rates ... offers a wealth of technological innovations that ...
The precise, fully reusable R-100 Pullback Device is an invaluable tool during plaque volumetric analysis....
... clinically valuable, device-derived information applicable to ... help specialty physicians discern if the ... or deteriorating. For example, heart failure ... InSync Sentry™ CRT-D system can use ...
... a 28 amino-acid lipophilic peptide with a ... serine residue three, that is primarily expressed ... the mucosa of the fundus of the ... to those of leptin. Ghrelin stimulates food ...
Medicine Products: